Related Experiment Video
Updated: May 11, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
[Biologics and mycobacterial diseases]
Kazunari Tsuyuguchi1, Tomoshige Matsumoto
1Department of Infectious Diseases, Clinical Research Center, NHO Kinki-chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai-shi, Osaka 591-8555, Japan. tsuyuguchi@kch.hosp.go.jp
Biologics for rheumatoid arthritis increase tuberculosis risk, necessitating better screening with QuantiFERON tests. New guidelines are proposed for managing latent tuberculosis infection and nontuberculous mycobacterial diseases in patients on these treatments.
Area of Science:
- Rheumatology
- Infectious Diseases
- Immunology
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drug Products: Biologics, Biosimilars and Interchangeables
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

